Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a new financing round led by Vertex Ventures. Fosun Pharma and Kaitai Capital also participated in the round. The proceeds will be used to support technology research and development (R&D), talent recruitment, and laboratory construction.
Company Profile and Pipeline
Founded in 2021, PrimeLink Bio is focused on the construction of a drug delivery platform and the development of antibody-drug conjugates (ADCs). The company aims to enhance its capabilities in delivering innovative therapies through advanced drug delivery systems. PrimeLink Bio operates an R&D center in Suzhou Industrial Park and expects to make an investigational new drug (IND) filing for its lead drug candidate in 2024.
Future Plans
With the new funding, PrimeLink Bio plans to accelerate its R&D efforts, recruit top talent in the field, and expand its laboratory facilities. This strategic move will help the company advance its pipeline of ADCs and other innovative drug candidates, positioning it for future growth in the global pharmaceutical market.-Fineline Info & Tech
